Not all individuals with CLL require therapy. Irrespective of all recent advancements, the iwCLL however endorses watchful observation for patients with asymptomatic disorder.86 This suggestion relies on not less than two randomized trials evaluating observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).1